Swiss approve insurance cover for Novartis, Gilead cell therapies [Reuters]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Reuters
Swiss approve insurance cover for Novartis, Gilead cell therapies ZURICH, Dec 6 (Reuters) - The Swiss government approved on Friday health insurance coverage for CAR-T cell therapies from Novartis and Gilead Sciences, which can cost hundreds of thousands of dollars per patient. In this form of therapy, patients’ white blood cells are genetically modified to attack cancer cells. The health department said the decision covered Novartis’s Kymriah and Gilead’s Yescarta. “The contract between hospitals and the health insurers will be approved until the end of 2020, granting the affected patients immediate access to these therapies,” the government said after a cabinet meeting.
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences Announces First Quarter 2024 Financial ResultsBusiness Wire
- Built environment thought leaders discuss pathways to circular economy at Tarkett's third annual Circularity Summit [Yahoo! Finance]Yahoo! Finance
- Notable earnings after Thursday's close [Seeking Alpha]Seeking Alpha
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at HSBC Holdings plc from a "reduce" rating to a "hold" rating. They now have a $69.00 price target on the stock.MarketBeat
- Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? [Seeking Alpha]Seeking Alpha
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- 4/1/24 - Form 144
- GILD's page on the SEC website